This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ICG138

iCell Gene Therapeutics

Drug Names(s): ICG 138, ICG-138

Description: ICG138 is a chimeric antigen receptor engineered T-cell that simultaneously expresses two undisclosed scFV anibody domains.


ICG138 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug